New Head of Blue Orchid Marketing Rethinking Digital Marketing for Podiatrists Nationwide

Blue Orchid Marketing, a digital marketing agency specializing in marketing solutions for podiatrists, recently announced Shaun Zaken as its new owner.
 
The company cites Zaken's history as a content creator in Hollywood, saying this brings a unique and fresh perspective to the world of digital marketing, especially for podiatrists. Blue Orchid says Zaken’s “keen storytelling abilities, combined with a deep understanding of engaging audiences, make him a formidable force in the industry.”
 
"At Blue Orchid Marketing, we’re all about delivering unique, personal messages that help our clients connect with their patients to remain top of mind,” Zaken said in a press release. “I'm excited to leverage my storytelling expertise to grow podiatry practices nationwide in a meaningful, impactful way.”
 
Blue Orchid notes that under Zaken’s guidance, the agency will continue to elevate its offerings and expand its reach, ensuring professional practices across the country have access to cutting-edge digital marketing strategies that amplify their success. Most recently, the company says Zaken created a new position, Director of Client Services, and recruited Kimberly Chabot for the role.
 
Click here for more info.

Study: MolecuLight Can Help Level Racial Disparity in Wound Care Outcomes

MolecuLight Inc. recently announced the publication of “Skin Pigmentation Impacts the Clinical Diagnosis of Wound Infection: Imaging of Bacterial Burden to Overcome Diagnostic Limitations” in the Journal of Racial and Ethnic Health Disparities. The company says the study addresses the extremely relevant and pressing issue of health care inequities as they apply to wound care, namely:

• A lack of clinical training and educational resources on diverse skin tones,
• An implicit/unconscious racial bias by providers, and
• A lack of diagnostic tools and approaches that address the unique clinical attributes of patients with different skin tones, most pronounced in those in the high pigmentation range.

Click here for a clinical photo.

The study of 350 chronic wounds aimed to determine how the perception of clinical signs and symptoms of infection (CSS) differs depending on the patient’s skin tone and to determine whether MolecuLight’s fluorescence imaging could offer a more objective diagnostic solution.
 
The study found that:

• Clinicians were far less likely to flag bacterial-laden wounds on highly pigmented skin as being problematic, highlighting the need for objective diagnostic solutions.
• The risk of racialized health inequities in wound care is higher when the diagnosis of pathogenic bacteria and infection are missed, resulting in treatment/intervention delays. This leads to an increased risk of complications and poorer outcomes. It has been well established in the literature that Black long-term care residents are far more likely to suffer from complications and die because of an infection than their Caucasian counterparts. Diagnostic limitations contribute to this inequity. 
• Fluorescence imaging has great potential to serve as a more objective and equitable indicator of wound bacteria across all skin tones.

 Click here for more info.